Status:
UNKNOWN
ESCAP-2020-CPHG: Treatment Strategies Follow-up Implemented During the First Three Years Following Primary Lung Cancer (PLC) Diagnosed in KBP-2020-CPHG Cohort Patients
Lead Sponsor:
Collège des Pneumologues des Hôpitaux Généraux
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The prognosis for primary lung cancer (PLC) is very limited. In France, patients diagnosed for PLC in 2010 and followed in Respiratory Medicine or Oncology department of a General Hospital Centre had ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020\*
- Follow-up by a lung specialist at a General Hospital
- Oral informed consent \* date of collected sample
Exclusion
- Age \< 18 years
- Secondary lung cancer
- Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery
- Previous enrolment in the study
- Freedom deprived patient following a legal or administrative decision
- Patient unable to give his(her) consent
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT04419155
Start Date
January 1 2020
End Date
December 31 2023
Last Update
June 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Collège des Pneumologues des Hôpitaux Généraux (CPHG) (General Hospital Pulmonologists College)
Paris, France, 75006